OTLK - Outlook Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

192.7M

Cash

47.23M

Avg Qtr Burn

-14.56M

Short % of Float

17.88%

Insider Ownership

36.22%

Institutional Own.

33.26%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Wet age-related macular degeneration , Eye disease	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Wet age-related macular degeneration , Eye disease	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Eye disease	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Diabetes, Eye disease , BK virus, Adenovirus, Epstein-Barr virus, Human herpesvirus 6, Cytomegalovirus, Diabetic macular edema	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.